- Home
- ROOT vs ARVN Comparison
ROOT vs ARVN Comparison
Compare ROOT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROOT | ARVN |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.6M | 781.0M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ROOT | ARVN |
|---|---|---|
| Price | $48.22 | $13.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $108.40 | $15.71 |
| AVG Volume (30 Days) | 365.8K | ★ 733.1K |
| Earning Date | 05-28-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.96 | ★ 58.84 |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,517,100,000.00 | $262,600,000.00 |
| Revenue This Year | $10.08 | N/A |
| Revenue Next Year | $12.63 | N/A |
| P/E Ratio | $20.39 | ★ N/A |
| Revenue Growth | ★ 28.95 | N/A |
| 52 Week Low | $46.63 | $5.90 |
| 52 Week High | $181.14 | $18.45 |
Technical Indicators
Market Signals| Indicator | ROOT | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 33.14 | 57.02 |
| Support Level | N/A | $11.07 |
| Resistance Level | $88.63 | $13.97 |
| Average True Range (ATR) | 3.47 | 0.76 |
| MACD | -0.73 | 0.11 |
| Stochastic Oscillator | 10.82 | 83.05 |
Price Performance
Historical ComparisonAbout ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.